A

    ARS Pharmaceuticals, Inc (SPRY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.89
    -0.14 (-2.32%)

    Market Cap: $596.68M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    46%(11/24)
    Avg Surprise
    +36.49%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.30
    Range$-0.38 - $-0.24
    3 analysts
    EPS RevisionsNo revisions (7d)
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-0.33-8.8%
    60d ago$-0.33-8.8%
    30d ago$-0.27+11.0%
    7d ago$-0.27+11.0%
    Current$-0.30
    Revenue Consensus
    $45M
    Range$37M - $54M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.51
    Range$-0.70 - $-0.29
    3 analysts
    Revenue Consensus
    $34M
    Range$23M - $51M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.51---
    Sep 26EST
    		-$-0.30---
    Jun 26
    Reported Aug 12
    		$-0.63$-0.55-14.55%Miss-37.0%
    Mar 26
    Reported May 15
    		$-0.61$-0.53-15.09%Miss-74.3%
    Dec 25
    Reported Mar 9
    		$-0.42$-0.42+1.08%Beat-182.4%
    Sep 25
    Reported Nov 10
    		$-0.52$-0.49-6.12%Miss-160.0%
    Jun 25
    Reported Aug 13
    		$-0.46$-0.51+9.80%Beat-253.8%
    Mar 25
    Reported May 14
    		$-0.35$-0.36+2.78%Beat-218.2%
    Dec 24
    Reported Mar 20
    		$0.51$-0.12+534.04%Beat+828.6%
    Sep 24
    Reported Nov 13
    		$-0.20$-0.14-42.86%Miss-25.0%
    Jun 24
    Reported Aug 6
    		$-0.13$-0.11-18.18%Miss+27.8%
    Mar 24
    Reported May 9
    		$-0.11$-0.11+0.00%Beat+31.3%
    Dec 23
    Reported Mar 21
    		$-0.07$-0.14+50.00%Beat-109.1%
    Sep 23
    Reported Nov 9
    		$-0.16$-0.18+11.11%Beat+68.0%
    Jun 23
    Reported Aug 10
    		$-0.18$-0.16-12.50%Miss+67.3%
    Mar 23
    Reported May 15
    		$-0.16$-0.15-6.67%Miss+77.1%
    Dec 22
    Reported Mar 23
    		$0.77$-0.13+692.31%Beat+214.9%
    Sep 22
    Reported Nov 2
    		$-0.50$-0.35-42.86%Miss+23.1%
    Jun 22
    Reported Aug 11
    		$-0.55$-0.48-14.58%Miss+21.4%
    Mar 22
    Reported May 12
    		$-0.70$-0.54-29.63%Miss-29.6%
    Dec 21
    Reported Mar 31
    		$-0.67$-0.70+4.29%Beat+51.1%
    Sep 21
    Reported Nov 10
    		$-0.65$-0.67+2.99%Beat+7.1%
    Jun 21
    Reported Aug 12
    		$-0.70$-0.53-32.08%Miss-
    Mar 21
    Reported May 13
    		$-0.54$-0.35-54.29%Miss-
    Dec 20
    Reported Mar 29
    		$-1.37$-0.49-179.59%Miss-
    Sep 20
    Reported Nov 10
    		$-0.70$-1.10+36.36%Beat-

    Key Metrics

    Valuation
    P/E Ratio-2.70EV/EBITDA-9.88x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-184.20%Operating Margin-182.60%
    ROE-210.30%ROIC-155.97%
    Financial Health
    Debt/Equity7.73xInterest CoverageN/A
    Current Ratio3.48xQuick Ratio3.28x
    Trading Statistics
    Beta0.97Avg Volume1.86M
    52-Week High$13.1552-Week Low$4.91

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.89
    SMA 20$5.82
    SMA 50$6.86
    SMA 200$8.63
    EMA 10$5.86
    EMA 20$5.96
    EMA 50$6.64
    EMA 200$8.53

    MACD

    Line: -0.22Signal: -0.30Hist: 0.09

    ADX

    ADX: 26.0+DI: 24.8-DI: 32.1

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down24.0
    PSAR$6.47

    Bollinger Bands

    Upper Band$6.50
    Lower Band$5.14
    %B Position2342%(Upper)
    Band Width0.55

    RSI (14-Day)

    Neutral
    46.5

    Momentum Oscillators

    Stoch %K62.2
    Stoch %D55.1
    Williams %R-43.7
    ROC (10d)4.2%
    Momentum0.24
    CCI (20d)31.7
    MFI (14d)52.1

    Volatility Measures

    ATR (14d)$0.42(7.1%)
    StdDev (20d)0.34
    Hist Vol91.6%(High)

    Volume Flow

    VWAP$5.92
    OBV-37.0M
    AD Line-9.8M
    CMF (20d)0.268

    Volume Metrics

    Avg Vol (20d)1.9M
    Vol Ratio0.6x
    VWMA (20d)$5.79

    Pivot Points

    R3$6.37
    R2$6.24
    R1$6.14
    Pivot Point$6.01
    S1$5.91
    S2$5.78
    S3$5.68

    Advanced Oscillators

    TSI-12.50
    Ultimate Osc48.3
    KST-86.75

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$33.66M$22.68M$28.09M$32.50M$15.72M$7.97M$86.58M$2.07M$500,000$0$-30,000$0
    Cost of Revenue$12.85M$6.29M$-1,094,000$0$4.98M$1.09M$977,000$0$0$0$3.40M$0
    Gross Profit$20.81M$16.39M$29.18M$32.50M$10.73M$6.88M$85.60M$2.07M$500,000$0$-3,404,000$0
    Operating Expenses$82.28M$76.54M$70.65M$85.69M$58.35M$44.06M$38.41M$23.82M$15.84M$13.19M$10.23M$17.98M
    R&D$4.70M$4.34M$3.44M$2.75M$4.04M$2.95M$3.03M$4.42M$6.90M$5.23M$3.40M$3.00M
    SG&A$77.58M$72.20M$59.95M$74.75M$54.31M$41.10M$35.49M$19.28M$8.94M$7.96M$6.82M$14.98M
    Operating Income$-61,465,000$-60,145,000$-41,465,000$-53,192,000$-47,614,000$-37,177,000$47.20M$-21,748,000$-15,340,000$-13,192,000$-10,226,000$-17,978,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$874,000$473,000$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-62,339,000$-60,618,000$-38,167,000$-51,151,000$-44,883,000$-33,940,000$50.22M$-19,128,000$-12,516,000$-10,292,000$-7,168,000$-14,866,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-62,339,000$-60,618,000$-41,324,000$-51,151,000$-44,883,000$-33,940,000$49.93M$-19,128,000$-12,516,000$-10,292,000$-7,168,000$-14,866,000
    EBITDA$-62,573,000$-61,211,000$-42,051,000$-51,852,000$-46,071,000$-35,621,000$48.71M$-20,933,000$-14,402,000$-12,261,000$-8,883,000$-16,405,000
    EBIT$-62,339,000$-60,618,000$-41,465,000$-51,151,000$-44,883,000$-33,940,000$50.22M$-19,128,000$-12,516,000$-10,292,000$-7,168,000$-14,866,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SPRY

    News

    SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

    Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for alleged securities fraud. The lawsuit claims ARS made false and misleading statements regarding the timeline for insurance coverage of its drug neffy, impacting its commercialization. Investors who purchased SPRY shares between March 9, 2026, and June 24, 2026, are encouraged to contact SBS to discuss lead plaintiff appointments before the October 5, 2026 deadline.

    WBOC TV•8/25/26•
    Bearish

    Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

    Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) for alleged federal securities law violations. The lawsuit claims ARS Pharmaceuticals made misleading statements and concealed adverse facts regarding the expected timeline for expanded insurance coverage for their product, neffy. Investors who suffered losses are encouraged to join the case and have until October 5, 2026, to request lead plaintiff appointment.

    GlobeNewswire•8/24/26•
    Bearish

    SPRY Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in ARS Pharmaceuticals Inc. Securities Class Action - Contact Levi & Korsinsky

    A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) due to alleged misrepresentations regarding CVS Caremark's coverage for neffy. The lawsuit claims the company misled investors about the effective date of expanded coverage, causing a significant stock drop. Investors who purchased SPRY stock between March 9, 2026, and June 24, 2026, may be affected, with a lead plaintiff deadline set for October 5, 2026.

    GlobeNewswire•8/24/26•
    Bearish

    Important Notice to Long-Term Shareholders of ARS

    Grabar Law Office is investigating potential breaches of fiduciary duties and securities fraud claims on behalf of long-term shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), Roblox Corporation (NYSE: RBLX), Symbotic Inc. (NASDAQ: SYM), and The Simply Good Foods Company (NASDAQ: SMPL). Shareholders who purchased shares before specified dates and still hold them are encouraged to contact the law office to learn about seeking corporate reforms and other remedies.

    GlobeNewswire•8/24/26•
    Bearish

    Important Notice to Long-Term Shareholders of ARS

    Grabar Law Office is investigating potential breaches of fiduciary duty and securities fraud claims against ARS Pharmaceuticals, Roblox Corporation, Symbotic Inc., and The Simply Good Foods Company. Shareholders who held shares of these companies prior to specific dates are encouraged to contact the law office to seek corporate reforms and other remedies. The allegations involve issues such as misleading statements about product coverage, earnings growth, deployment acceleration, and acquisition integration challenges.

    GlobeNewswire•8/24/26•
    Neutral

    Frequently Asked Questions About SPRY

    Does SPRY pay dividends?
    ARS Pharmaceuticals, Inc (SPRY) does not currently pay a regular dividend.
    What is SPRY's market cap?
    ARS Pharmaceuticals, Inc (SPRY) has a market capitalization of $596.68M with a current stock price of $5.89.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In